Savant Capital LLC Invests $218,000 in BridgeBio Pharma, Inc. $BBIO

Savant Capital LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the 2nd quarter, Holdings Channel reports. The fund acquired 5,051 shares of the company’s stock, valued at approximately $218,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma in the first quarter worth approximately $35,000. CWM LLC raised its stake in shares of BridgeBio Pharma by 12.8% in the 1st quarter. CWM LLC now owns 5,261 shares of the company’s stock worth $182,000 after buying an additional 598 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of BridgeBio Pharma in the second quarter valued at $202,000. DAVENPORT & Co LLC bought a new position in BridgeBio Pharma during the second quarter valued at about $207,000. Finally, Commerce Bank acquired a new position in BridgeBio Pharma during the first quarter worth about $209,000. Institutional investors own 99.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BBIO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, October 8th. Cowen reiterated a “positive” rating on shares of BridgeBio Pharma in a report on Thursday, October 30th. JPMorgan Chase & Co. raised their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Wall Street Zen upgraded shares of BridgeBio Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, The Goldman Sachs Group increased their price objective on BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Twenty analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.37.

Insider Buying and Selling

In other news, Director Hannah Valantine sold 25,484 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $66.07, for a total value of $1,683,727.88. Following the completion of the sale, the director directly owned 7,465 shares of the company’s stock, valued at $493,212.55. This represents a 77.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $54.78, for a total transaction of $2,191,200.00. Following the sale, the chief executive officer owned 855,686 shares of the company’s stock, valued at approximately $46,874,479.08. This represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 603,048 shares of company stock worth $37,702,289 over the last ninety days. 18.20% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Stock Down 0.1%

BBIO opened at $65.54 on Thursday. The firm has a market capitalization of $12.63 billion, a P/E ratio of -15.68 and a beta of 1.39. The stock has a fifty day moving average of $57.23 and a 200-day moving average of $48.21. BridgeBio Pharma, Inc. has a 12-month low of $22.05 and a 12-month high of $69.48.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). The firm had revenue of $120.70 million during the quarter, compared to analyst estimates of $107.71 million. The company’s quarterly revenue was up 4318.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.86) EPS. On average, analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.